This company has been acquired
Opiant Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Opiant Pharmaceuticals has a total shareholder equity of $20.5M and total debt of $13.8M, which brings its debt-to-equity ratio to 67.1%. Its total assets and total liabilities are $42.0M and $21.4M respectively.
Key information
67.12%
Debt to equity ratio
US$13.76m
Debt
| Interest coverage ratio | n/a |
| Cash | US$35.38m |
| Equity | US$20.50m |
| Total liabilities | US$21.45m |
| Total assets | US$41.95m |
Recent financial health updates
Recent updates
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates
Aug 13
Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment
Aug 08Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate
Aug 05Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts
Mar 21Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 19These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well
Nov 17Opiant Pharmaceuticals: Assessing Recent Insider Buying
Sep 19Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts
Aug 07Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
Jun 09The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts
Mar 06News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts
Mar 05Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.
Jan 27Financial Position Analysis
Short Term Liabilities: OPNT's short term assets ($38.5M) exceed its short term liabilities ($7.0M).
Long Term Liabilities: OPNT's short term assets ($38.5M) exceed its long term liabilities ($14.4M).
Debt to Equity History and Analysis
Debt Level: OPNT has more cash than its total debt.
Reducing Debt: OPNT's debt to equity ratio has increased from 0% to 67.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OPNT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: OPNT has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 27.7% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/03 04:57 |
| End of Day Share Price | 2023/03/01 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Opiant Pharmaceuticals, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Carl Byrnes | Northland Capital Markets |